These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17500103)

  • 21. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vaccine preparedness--are we ready for the next influenza pandemic?
    Wright PF
    N Engl J Med; 2008 Jun; 358(24):2540-3. PubMed ID: 18550873
    [No Abstract]   [Full Text] [Related]  

  • 23. Aflunov(®): a prepandemic influenza vaccine.
    Gasparini R; Amicizia D; Lai PL; Panatto D
    Expert Rev Vaccines; 2012 Feb; 11(2):145-57. PubMed ID: 22309663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Influenza vaccine].
    Horimoto T; Murakami S; Kawaoka Y
    Nihon Rinsho; 2008 Oct; 66(10):2013-8. PubMed ID: 18939506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre- or post-pandemic influenza vaccine?
    Osterhaus AD
    Vaccine; 2007 Jun; 25(27):4983-4. PubMed ID: 17555851
    [No Abstract]   [Full Text] [Related]  

  • 26. Seasonal influenza vaccination may mitigate the potential impact of an H5N1 pandemic.
    Qin CF; Qin ED
    Chin Med J (Engl); 2008 Aug; 121(15):1481-3. PubMed ID: 18959131
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a mucosal vaccine for influenza viruses: preparation for a potential influenza pandemic.
    Hasegawa H; Ichinohe T; Tamura S; Kurata T
    Expert Rev Vaccines; 2007 Apr; 6(2):193-201. PubMed ID: 17408369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Designing vaccines for pandemic influenza.
    Horimoto T; Kawaoka Y
    Curr Top Microbiol Immunol; 2009; 333():165-76. PubMed ID: 19768405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness.
    Wkly Epidemiol Rec; 2015 Mar; 90(12):109-20. PubMed ID: 25796641
    [No Abstract]   [Full Text] [Related]  

  • 31. Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.
    Kreijtz JH; Osterhaus AD; Rimmelzwaan GF
    Hum Vaccin; 2009 Mar; 5(3):126-35. PubMed ID: 18948744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Study on the immunogenicity of adeno-vector vaccine against H5N1 influenza A virus].
    Zhang XG; Li KB; Ma J; Wang NF; Zhang XM; Sang YH; Dong J; Xu H; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):97-9. PubMed ID: 20104746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. H5N1 viruses and vaccines.
    Subbarao K; Luke C
    PLoS Pathog; 2007 Mar; 3(3):e40. PubMed ID: 17335350
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update].
    Loulergue P; Launay O
    Med Sci (Paris); 2009; 25(8-9):719-25. PubMed ID: 19765386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells: implications for pandemic preparedness.
    Tseng YF; Hu AY; Huang ML; Yeh WZ; Weng TC; Chen YS; Chong P; Lee MS
    PLoS One; 2011; 6(10):e24057. PubMed ID: 22022351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study.
    Díez-Domingo J; Garcés-Sanchez M; Baldó JM; Planelles MV; Ubeda I; JuBert A; Marés J; Moris P; Garcia-Corbeira P; Dramé M; Gillard P
    Pediatr Infect Dis J; 2010 Jun; 29(6):e35-46. PubMed ID: 20375709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. H5N1 vaccines in humans.
    Baz M; Luke CJ; Cheng X; Jin H; Subbarao K
    Virus Res; 2013 Dec; 178(1):78-98. PubMed ID: 23726847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Engineering by reverse genetics and characterization of the new reassortant influenza virus strain H5N1].
    Zeberezhnyĭ AD; Grebennikova TV; Vorkunova GK; Yuzhakov AG; Kostina LV; Norkina SN; Aliper TI; Nepoklonov EA; Lvov DK
    Vopr Virusol; 2014; 59(6):23-7. PubMed ID: 25929032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines for pandemic influenza. Preface.
    Compans RW; Orenstein WA
    Curr Top Microbiol Immunol; 2009; 333():v-viii. PubMed ID: 19787865
    [No Abstract]   [Full Text] [Related]  

  • 40. The antigenic architecture of the hemagglutinin of influenza H5N1 viruses.
    Velkov T; Ong C; Baker MA; Kim H; Li J; Nation RL; Huang JX; Cooper MA; Rockman S
    Mol Immunol; 2013 Dec; 56(4):705-19. PubMed ID: 23933511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.